As of May, 8 The EPS for BELLUS Health Inc. (BLU) Expected At $-0.01

April 17, 2018 - By Richard Doty

BELLUS Health Inc. (TSE:BLU) Corporate Logo

BELLUS Health Inc. (TSE:BLU)’s quarterly earnings will be announced On May, 8., RTT reports. Analysts predict $-0.01 earnings per share. That’s $0.03 down or 150.00 % from 2017’s earnings of $0.02. After $-0.03 EPS report last quarter, Wall Street now sees -66.67 % EPS growth of BELLUS Health Inc.. Its shares touched $0.495 on during the last trading session after 1.02% change.Currently BELLUS Health Inc. is after 0.00% change in last April 17, 2017. BLU has 18,459 shares volume. The stock underperformed the S&P500 by 11.55%.

BELLUS Health Inc., a biopharmaceutical company, engages in developing novel therapeutics for conditions with high unmet medical need.The firm is valued at $59.15 million. The Company’s pipeline of projects include BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough; KIACTA, a novel drug candidate for the treatment of patients suffering from active pulmonary sarcoidosis, a rare fatal inflammatory condition that affects the lungs; and Shigamab for the treatment of hemolytic uremic syndrome caused by Shiga toxin-producing E. coli.Currently it has negative earnings. The firm also has economic interests in various other partnered drug development projects, including AMO-01 for Fragile X Syndrome and ALZ-801 for APOE4 homozygous Alzheimer's disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.